In hematological malignancies, several clinical trials using CXCR4 antagonists or targeting CXCR4 have also been conducted, but some completed clinical trials (NCT01120457, NCT04274738, NCT01236144, NCT01010880) have not posted experimental results. This evidence concerns the gene CXCR4 and hematologic disorder.